60 Binney St
About bluebird bio
bluebird bio is leading the gene therapy revolution. We have nearly 15 years of scientific and clinical experience at the forefront of gene therapy, with deep expertise in rare diseases and immuno-oncology, a proven scientific and lentiviral-based manufacturing platform, and a complementary set of tools such as gene editing.
We are a patient- and purpose-driven, product-oriented organization. Our diverse flock of bluebirds is united by a singular focus: a passionate commitment to changing the lives of patients and supporting each other on this journey. At bluebird bio, we will work like crazy with a never-give-up, little-but-mighty attitude, as exemplified by our namesake, the Eastern Bluebird.
we are always innovating, never stopping and never giving up.
Stock symbol: BLUE
Stock exchange: NASDAQ
Our birds are constantly reminded of the difference they can make on the lives of patients and in the lives of their fellow birds – no matter what their title may be. Whether it’s running a successful experiment in the lab, developing a new and efficient process for your team, being an inspiring mentor for those around you, or always being a friendly face in the morning, we can all make an impact and we can all make a difference. How will you Make Your Mark?
287 articles with bluebird bio
bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases
bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases, including haemophilia.
In the latest Ideal Employer Survey, BioSpace readers chimed in their thoughts on which companies across the biotech and biopharma industries were doing the most interesting and meaningful work.
The deal will last three years, with a top priority to develop a gene therapy for hemophilia A.
bluebird bio, Inc. announced that it has appointed William R. Sellers, M.D. to its Board of Directors.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
BioSpace, the leader in life sciences news and careers, today announced that Genentech, Pfizer, Merck, Amgen and Novartis landed in the top five spots of their latest Ideal Employer report.
bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress
Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free at up to Five Years of Follow-up
There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.
bluebird bio to Present Data from Clinical Development Program of Lenti-DTM Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress
bluebird bio, Inc. (Nasdaq: BLUE) announced that updated data from the clinical development program for its investigational Lenti-D™ gene therapy in patients with cerebral adrenoleukodystrophy (CALD) will be presented at the 13th European Pediatric Neurology Society (EPNS) Congress, to be held September 17 – 21, 2019 in Athens, Greece.
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in September
bluebird bio, Inc. reported financial results and business highlights for the second quarter ended June 30, 2019.
6/17/2019Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
bluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease (SCD) at 24th European Hematology Association (EHA) Congress
In patients who were at least six months post-treatment with LentiGlobin for SCD, median level of abnormal sickle hemoglobin (HbS) was reduced to ≤50 percent of total Hb
bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress
bluebird bio, Inc. announced updated results from the completed Phase 1/2 Northstar study, and new data from the Phase 3 Northstar-2 and Phase 3 Northstar-3 clinical studies of its LentiGlobin® gene therapy for patients with transfusion-dependent β-thalassemia, at the 24th European Hematology Association Congress in Amsterdam, the Netherlands.
Cambridge, Mass.-based bluebird bio released updated results from three clinical trials of its LentiGlobin gene therapy for transfusion-dependent Beta-thalassemia.
bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding βA-T87Q-globin gene) Approval
bluebird bio, Inc. announced that the company will host a live webcast to review new data presented at the European Hematology Association Annual Meeting, and to discuss the approval of ZYNTEGLO® on Friday, June 14 at 8:00 a.m. ET.
This is the largest fund in the 12 years Third Rock has been in existence. The company indicates it will use the money to seed 10 to 12 life science companies.
bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older
ZYNTEGLO is the first gene therapy approved for transfusion-dependent β-thalassemia (TDT)
bluebird bio, Inc. announced that the Company will hold a conference call to discuss data presented at the European Hematology Association Annual Meeting on Friday, June 14 at 8:00 am ET.
bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent β-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress
Additional follow-up from the completed Phase 1/2 Northstar (HGB-204) study of LentiGlobin in adolescents and adults with TDT